Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.
The anti-mitotic drug vindesine was coupled chemically to a monoclonal antibody raised originally against the human osteogenic sarcoma cell line, 791T. The cytotoxicity of the conjugate in vitro was tested, in comparison with free vindesine, against sarcoma 791T and other antigenically cross-reactive osteogenic sarcoma-cell lines, and also against tumour cell lines which have no detectable reaction with the monoclonal antibody. Continuous exposure of cultured 791T cells indicated that the vindesine was partially inactivated following conjugation since the conjugate was less toxic than the free drug. However, antibody-binding activity was essentially preserved following conjugation. Despite diminished drug activity in the conjugate, assays designed to mimic antibody binding to tumour in which target cells were treated with conjugate and washed before culture, showed selective cytotoxicity for osteogenic sarcoma lines with little or no effect on non-cross reactive control cells. In comparison, free vindesine was toxic equally for all cell lines and free antibody was non-toxic. These studies indicate that conjugation of a cytotoxic agent to a monoclonal antibody can confer on that agent selectivity for a particular target cell type which is recognised by the antibody.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001667:Binding, Competitive; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003429:Cross Reactions; D006801:Humans; D012516:Osteosarcoma / Q000276:immunology / Q000473:pathology*; D012513:Sarcoma, Experimental / Q000276:immunology / Q000473:pathology; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014751:Vindesine
D000911:Antibodies, Monoclonal; D014747:Vinblastine; D014751:Vindesine